What is Roth Capital's Estimate for Enovis Q3 Earnings?

Key Points

• Roth Capital has lowered its earnings per share estimate for Enovis for Q3 2025 from $0.69 to $0.66, with a full-year estimate of $2.79 per share.
• Multiple analysts have adjusted their price targets for Enovis, with Needham & Company lowering its target from $57.00 to $49.00, reflecting a more cautious outlook on the stock's performance.
• Enovis reported earnings of $0.79 per share for the last quarter, exceeding expectations, and showed a year-over-year revenue increase of 7.5%, totaling $564.5 million.

Enovis Corporation (NYSE:ENOV - Free Report) - Equities researchers at Roth Capital cut their Q3 2025 earnings per share (EPS) estimates for Enovis in a report released on Thursday, August 7th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.66 per share for the quarter, down from their prior forecast of $0.69. The consensus estimate for Enovis' current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis' Q2 2026 earnings at $0.81 EPS.

Several other equities research analysts have also recently issued reports on the company. UBS Group cut their price target on Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Evercore ISI cut their target price on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Canaccord Genuity Group cut their target price on Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Needham & Company LLC dropped their price target on Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, JMP Securities dropped their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $51.00.

Enovis Stock Performance

Shares of NYSE:ENOV traded down $0.63 during trading on Monday, reaching $28.96. 360,847 shares of the stock were exchanged, compared to its average volume of 1,200,008. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53. The firm has a market cap of $1.66 billion, a PE ratio of -2.03 and a beta of 1.70. The stock has a 50-day moving average price of $30.43 and a 200-day moving average price of $34.92. Enovis has a 12 month low of $25.47 and a 12 month high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. The company had revenue of $564.50 million during the quarter, compared to analysts' expectations of $555.80 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. The business's revenue was up 7.5% on a year-over-year basis.

Institutional Trading of Enovis

A number of institutional investors and hedge funds have recently bought and sold shares of ENOV. US Bancorp DE grew its holdings in Enovis by 2.5% during the 1st quarter. US Bancorp DE now owns 19,031 shares of the company's stock worth $727,000 after acquiring an additional 462 shares during the period. Mariner LLC grew its holdings in Enovis by 16.8% during the 4th quarter. Mariner LLC now owns 7,925 shares of the company's stock worth $348,000 after acquiring an additional 1,142 shares during the period. Comerica Bank grew its holdings in Enovis by 22.9% during the 4th quarter. Comerica Bank now owns 49,560 shares of the company's stock worth $2,175,000 after acquiring an additional 9,224 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Enovis during the 4th quarter worth about $10,970,000. Finally, Southeastern Asset Management Inc. TN grew its holdings in Enovis by 60.6% during the 4th quarter. Southeastern Asset Management Inc. TN now owns 36,583 shares of the company's stock worth $1,605,000 after acquiring an additional 13,797 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.